HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol B is a phase I/II trial evaluating the safety and efficacy of dasatinib + venetocolax in combination with dexamethasone + Cyclophosphamide and cytarabine in children and AYA with R/R ped ALL/LBL whose tumor present with alterations in the MAPK/SRC pathway.

Trial Details

NCT ID

NCT05751044

Phase

PHASE1 / PHASE2

Sponsor

Princess Maxima Center for Pediatric Oncology

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

Dasatinib
Venetoclax
Dexamethasone
Cyclophosphamide
Cytarabine
intrathecal chemotherapy

Locations (sample)

Vienna, Austria|48.20849,16.37208
Ghent, Belgium|51.05,3.71667
Copenhagen, Denmark|55.67594,12.56553
Helsinki, Finland|60.16952,24.93545
Bordeaux, France|44.84124,-0.58046

Key Eligibility Criteria

Children between 1 year (≥ 12 months) and 18 years of age at the time of first diagnosis and less than 21 years at the time of inclusion
Performance status: Karnofsky performance status (for patients \>12 years of age) or Lansky Play score (for patients ≤12 years of age) ≥ 50% (Appen…
Written informed consent from parents/legal representative, patient, and age-appropriate assent before any study specific screening procedures are …
For all oral medications patients must be able to comfortably swallow capsules (except for those for which an oral solution is available or dissolv…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →